DrugId:  1
1. Name:  Pegademase bovine
2. Groups:  Approved
3. Description:  Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
4. Indication:  For treatment of adenosine deaminase deficiency
DrugId:  2
1. Name:  Fibrinolysin
2. Groups:  Investigational
3. Description:  Fibrinolysin (also known as bovine plasmin) is a bovine enzyme derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90,000 daltons. Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.
4. Indication:  Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
DrugId:  3
1. Name:  Rotavirus Vaccine
2. Groups:  Approved
3. Description:  Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration [2]. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains [1]. Rotarix is a live attenuated vaccine containing the 89-12 human strain [FDA Label]. Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection [2].
4. Indication:  Rotarix is indicated for prevention of rotavirus gastroenteritis caused by G1, G3, G4, and G9 types in infants aged 6-24 weeks [FDA Label].Rotateq is indicated for the prevention of rotavirus gastroenteritis caused by G1, G2, G3, G4, and G9 types in infants aged 6-32 weeks [1].
DrugId:  4
1. Name:  Beef
2. Groups:  Approved
3. Description:  Beef allergenic extract is used in allergenic testing.
4. Indication:  Not Available
DrugId:  5
1. Name:  Bacillus calmette-guerin substrain danish 1331 live antigen
2. Groups:  Investigational
3. Description:  BCG SSI has been used in trials studying Tuberculosis.
4. Indication:  Not Available
DrugId:  6
1. Name:  Tuberculin Purified Protein Derivative
2. Groups:  Approved
3. Description:  Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with Mycobacterium tuberculosis through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.
4. Indication:  Indicated as a diagnostic agent in Mantoux Test used to detect infection with Mycobacterium tuberculosis. 
DrugId:  7
1. Name:  Thrombin
2. Groups:  Approved, Investigational
3. Description:  Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin in the presence of calcium chloride. Thrombin requires no intermediate physiological agent for its action. It clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself.
4. Indication:  Not Available
DrugId:  8
1. Name:  BCG vaccine
2. Groups:  Investigational
3. Description:  BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
4. Indication:  Not Available
DrugId:  9
1. Name:  Casein
2. Groups:  Approved
3. Description:  Casein allergenic extract is used in allergenic testing.
4. Indication:  Not Available
DrugId:  10
1. Name:  Terizidone
2. Groups:  Approved, Investigational
3. Description:  Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.
4. Indication:  Not Available
DrugId:  11
1. Name:  Ethionamide
2. Groups:  Approved
3. Description:  A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
4. Indication:  For use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.
DrugId:  12
1. Name:  Aprotinin
2. Groups:  Approved, Investigational, Withdrawn
3. Description:  Aprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; after this was confirmed by follow-up studies, Trasylol was entirely and permanently withdrawn in May 2008, except - at least for the time being - for very restricted research use. [Wikipedia]
4. Indication:  For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
DrugId:  13
1. Name:  Delamanid
2. Groups:  Approved, Investigational
3. Description:  Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [1]. It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. Emergence of multidrug-resistant and extensively drug-resistant tuberculosis creates clinical challenges for patients, as the disease is associated with a higher mortality rate and insufficient therapeutic response to standardized antituberculosis treatments as Isoniazid and Rifampicin. Multidrug-resistant tuberculosis may also require more than 2 years of chemotherapy and second-line therapies with narrow therapeutic index [4]. In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background treatment regimen was associated with improved treatment outcomes and reduced mortality rate [1]. Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [6]. Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).
4. Indication:  Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability [6].
DrugId:  14
1. Name:  Pyrazinamide
2. Groups:  Approved, Investigational
3. Description:  A pyrazine that is used therapeutically as an antitubercular agent.
4. Indication:  For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
DrugId:  15
1. Name:  Technetium Tc-99m ciprofloxacin
2. Groups:  Investigational
3. Description:  99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in nuclear medical imaging There is currently controversy around the drug's ability to discriminate between sterile inflammation and bacterial versus nonbacterial infections.
4. Indication:  Investigated for use/treatment in infectious and parasitic disease (unspecified).
DrugId:  16
1. Name:  Sutezolid
2. Groups:  Investigational
3. Description:  Sutezolid has been used in trials studying the treatment of Tuberculosis.
4. Indication:  Not Available
DrugId:  17
1. Name:  Rifapentine
2. Groups:  Approved, Investigational
3. Description:  Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
4. Indication:  For the treatment of pulmonary tuberculosis.
DrugId:  18
1. Name:  Ethambutol
2. Groups:  Approved
3. Description:  An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
4. Indication:  For use, as an adjunct, in the treatment of pulmonary tuberculosis.
DrugId:  19
1. Name:  5-amino-1,3,4-thiadiazole-2-thiol
2. Groups:  Investigational
3. Description:  ATT has been investigated in Pulmonary Tuberculosis.
4. Indication:  Not Available
DrugId:  20
1. Name:  Viomycin
2. Groups:  Approved
3. Description:  Viomycin is a member of the tuberactinomycin family, a group of nonribosomal peptide antibiotics exhibiting anti-tuberculosis properties. The tuberactinomycin family is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis. Viomycin was the first member of the tuberactinomycins to be isolated and identified and was used to treat TB until it was replaced by the less toxic, but structurally related compound, capreomycin. The tuberactinomycins target bacterial ribosomes, binding RNA and disrupting bacterial protein biosynthesis. It is produced by the actinomycete Streptomyces puniceus, that binds to RNA and inhibits prokaryotic protein synthesis and certain forms of RNA splicing. [Wikipedia]
4. Indication:  Viomycin is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis.
DrugId:  21
1. Name:  Bedaquiline
2. Groups:  Approved
3. Description:  Bedaquiline is a bactericidal antimycobacterial drug. Chemically it is a diarylquinoline. FDA approved on December 28, 2012. 
4. Indication:  Bedaquiline is indicated as part of combination therapy in adults (â‰¥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). 
DrugId:  22
1. Name:  Bacillus calmette-guerin substrain tice live antigen
2. Groups:  Approved
3. Description:  Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.
4. Indication:  Not Available
DrugId:  23
1. Name:  Faropenem
2. Groups:  Investigational
3. Description:  Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.
4. Indication:  Not Available
DrugId:  24
1. Name:  Isoniazid
2. Groups:  Approved, Investigational
3. Description:  Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. [PubChem]
4. Indication:  For the treatment of all forms of tuberculosis in which organisms are susceptible.
DrugId:  25
1. Name:  Trypsin
2. Groups:  Approved, Vet approved
3. Description:  Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine. Trypsin contains a nucleophilic residue Ser in the enzyme active site which attacks the carbonyl moiety of the substrate peptide bond to form an acyl-enzyme intermediate [1]. This nucleophilic attack is facilitated by the catalytic triad consisting of histidine-57, aspartate-102, and serine-195. Trypsin also contains an oxyanion hole that stabilizes the charge negative charge on the carbonyl oxygen atom formed from the cleavage of peptide bonds. Therapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is intended to aid in digestion when administered orally.
4. Indication:  Not Available
